Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland

BLACH, Sarah, et al.

Abstract

BACKGROUND AND AIMS: A previous analysis of hepatitis C virus (HCV)-related healthcare costs in Switzerland found that the annual healthcare costs of untreated HCV infection (excluding antiviral treatment) could increase by more than 25 million Swiss francs (CHF) between 2013 and 2030. Since that publication, highly efficacious direct-acting antiviral therapies (DAAs) have become available, making HCV elimination a possibility. This analysis quantifies the clinical and economic burden of HCV intervention strategies over the next 15 years. METHODS: A model was developed to estimate the future clinical and economic burden of HCV infection if patients are diagnosed and treated according to a historical paradigm (historical base case), or at higher levels without treatment reimbursement restrictions (Scenario 1). The infected population was tracked by age- and sex-defined cohorts, and associated direct medical costs (healthcare, screening, diagnostics and treatment) and quality-adjusted life years (QALYs) were calculated. Direct cost savings and the incremental cost-effectiveness ratio (ICER) were calculated to assess the [...]
Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland

Blach Saraha, Schaetti Christianb, Bruggmann Philipc, Negro Francescod, Razavi Homiea

a Center for Disease Analysis Foundation (CDAF), Lafayette, Colorado, USA
b Federal Office of Public Health, Public Health Directorate, Berne, Switzerland
c Arud Centres for Addiction Medicine, Zurich, Switzerland
d Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Genève, Switzerland

Summary
BACKGROUND AND AIMS: A previous analysis of hepatitis C virus (HCV)-related healthcare costs in Switzerland found that the annual healthcare costs of untreated HCV infection (excluding antiviral treatment) could increase by more than 25 million Swiss francs (CHF) between 2013 and 2030. Since that publication, highly efficacious direct-acting antiviral therapies (DAAs) have become available, making HCV elimination a possibility. This analysis quantifies the clinical and economic burden of HCV intervention strategies over the next 15 years.

METHODS: A model was developed to estimate the future clinical and economic burden of HCV infection if patients are diagnosed and treated according to a historical paradigm (historical base case), or at higher levels without treatment reimbursement restrictions (Scenario 1). The infected population was tracked by age- and sex-defined cohorts, and associated direct medical costs (healthcare, screening, diagnostics and treatment) and quality-adjusted life years (QALYs) were calculated. Direct cost savings and the incremental cost-effectiveness ratio (ICER) were calculated to assess the economic impact of each scenario. Additionally, we generated a net-zero cost scenario (Scenario 2), assuming the same treatment paradigm as Scenario 1 but at the treatment price that would break even by 2031.

RESULTS: In the historical base case, annual direct costs are projected to decrease from 150 million (95% UI: 132–170 million) CHF in 2016 to 90 million (95% UI: 65–111 million) CHF in 2031. Cumulative direct costs are projected to reach 1.7 billion (95% UI: 1.2–2.0 billion) CHF by 2031. In Scenario 1, annual direct costs first increased to 175 million CHF by 2018, before declining to 44 million CHF by 2031. Cumulative direct costs in this scenario are projected to reach 1.8 billion CHF by 2031. For Scenario 2, the treatment price needed to achieve break-even by 2031 considering only direct costs would be 27,900 CHF per patient. By 2031, Scenarios 1 and 2 would gain 58,300 QALYs. In both scenarios, the ICER drops below the cost-effectiveness threshold of 78,000 CHF in 2018. Over the 15-year span, the ICER was determined to be 2,200 CHF for Scenario 1.

CONCLUSIONS: Increasing the number of patients treated and treating all fibrosis stages is cost-effective compared to the historical base case and could achieve break-even by 2031 at a price of 27,900 CHF.

Key words: hepatitis C virus, liver cirrhosis, hepatocellular carcinoma, Switzerland, cost-effectiveness, quality-adjusted life years, direct-acting antivirals

Introduction
Although the exact prevalence of the hepatitis C virus (HCV) in Switzerland is unknown, recent efforts by the Federal Office of Public Health (FOPH) suggest that in 2016 there were an estimated 39,500 (36,000–43,000) chronic infections nationwide [1]. Switzerland is a world leader in harm reduction efforts which minimize ongoing transmission among people who inject drugs [2]. However, previous research showed that HCV-related morbidity and
mortality are projected to increase by 2030, even as vi-
raemic prevalence continues to decline [3]. In the absence
of other interventions, healthcare costs will increase as the
infected population ages because late-stage liver disease
often requires costly healthcare procedures such as liver
transplantation [3]. An analysis of HCV-related healthcare
costs in Switzerland found that the annual healthcare costs
of untreated HCV (excluding antiviral treatment) could in-
crease from 86 (42–182) million Swiss francs (CHF) in
2013 to 112 (42–267) million CHF by 2030 [3]. This could
place further strain on the limited resources of the health-
care system, as the economic costs incurred increase as in-
fection progresses.

In 2014, experts from across the country collaborated
to propose a hepatitis elimination strategy, with the aim of
curtailing new infections and addressing the harmful and
costly impact of HCV as the prevalent population ages
[4]. In previous modelling work, multiple scenarios with
changes to sustained virological response (SVR) rates,
medical eligibility, treatment uptake, diagnosis rates and
the number of patients treated were developed and com-
pared [3]. This analysis builds on those efforts by assessing
the forecasted impact and direct costs of intervention
strategies, i.e., screening, diagnostic, staging and treatment
costs, over the next 15 years. In particular, this analysis
seeks to evaluate the clinical impact and associated cost of
expanding treatment to patients in all fibrosis stages (≥F0)
compared with the status quo until October 2017 (treat-
ment of ≥F2 patients), and to calculate a treatment price
that is cost-saving (and cost-effective) by 2031. This analy-
sis was not undertaken to recommend any one therapy over
another; rather, it was conducted to estimate the impact of
growing access to direct-acting antivirals (DAAs) on the
HCV disease burden and associated costs.

Methodology

Overview of approach and model
We developed a disease burden and economic impact mod-
el, considering a formal Swiss healthcare sector perspec-
tive, to evaluate direct costs, health effects measured in
quality-adjusted life years (QALYs), and the incremental
cost-effectiveness ratio (ICER). Two HCV treatment sce-
narios, an intervention and a comparator scenario, were de-
veloped, considering the entire HCV RNA-positive pop-
ulation in Switzerland, and the outcomes were measured
over a 15-year time horizon from 2016 to 2031. Addition-
ally, a net-zero cost scenario was developed in which the
treatment price associated with the intervention scenario
was calculated to achieve break-even by 2031.

Future costs and health effects were discounted at an an-
nual rate of 3%. A scenario was considered cost-effective
when the ICER (calculated as net cost per QALY gained)
was lower than the 2015 Swiss gross domestic product
(GDP) per capita (78,000 CHF) [5].

Under the comparator, the “historical” base case, all individ-
uals aged 15 years and older with F2 or greater fibrosis
(on the METAVIR scale) were eligible for treatment start-
ing in 2016 (table 1). Under this base case, 2,000 ≥F2 pa-
patients were treated in 2016 at a price of 51,400 CHF. A

trend to reduce treatment numbers annually after 2016 was
applied to achieve a 50% reduction in the number of pa-
patients treated by 2030. This was intended to model the ex-
pected depletion of the pool of diagnosed and cared for pa-
patients which has been seen in the first few years of DAA
treatment across Western countries.

The intervention scenario, Scenario 1, followed the same
course as the historical base case through 2016 (table 1).
In October 2017, reimbursement restrictions for all DAAs
were lifted in Switzerland and the total number of patients

treated for the year increased to 3,000. Beginning in 2018,
4,250 ≥F0 patients were modelled as being treated annual-
ly, at a price of 31,000 CHF per patient [6]. Under this in-
tervention scenario, no changes were made to the number
of diagnosed patients. A net-zero cost scenario, Scenario 2,
was developed using the treatment paradigm of Scenario 1
but at a treatment price that would achieve zero net cost by
2031.

Model structure
The HCV disease progression model used in this analysis
has been described previously [7] and detailed model
structures, including model validation, are included in Ap-
pendix Section 1. Briefly, Swiss population, mortality and
HCV epidemiology data were used to populate and cali-
brate a Markov model that quantified the current and future
disease burden of HCV infection in Switzerland. The dis-
ease burden was measured through forecasted outcomes of
prevalence, mortality, and end-stage outcomes (including
hepatocellular carcinoma (HCC) and decompensated cir-
rhosis (DC)), considering the impact of current and future
interventions.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated</td>
<td>2,000</td>
<td>1,800</td>
<td>1,600</td>
<td>1,400</td>
<td>1,200</td>
</tr>
<tr>
<td>Newly diagnosed</td>
<td>1,100</td>
<td>1,100</td>
<td>1,100</td>
<td>1,100</td>
<td>1,100</td>
</tr>
<tr>
<td>Treatment-eligible fibrosis stages</td>
<td>≥ F2</td>
<td>≥ F2</td>
<td>≥ F2</td>
<td>≥ F2</td>
<td>≥ F2</td>
</tr>
<tr>
<td>New infections</td>
<td>700</td>
<td>700</td>
<td>700</td>
<td>700</td>
<td>700</td>
</tr>
<tr>
<td>Treatment-eligible ages</td>
<td>15+</td>
<td>15+</td>
<td>15+</td>
<td>15+</td>
<td>15+</td>
</tr>
<tr>
<td>SVR</td>
<td>95%</td>
<td>95%</td>
<td>95%</td>
<td>95%</td>
<td>95%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scenarios 1 and 2</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020–2030</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated</td>
<td>2,000</td>
<td>3,000</td>
<td>4,300</td>
<td>4,300</td>
<td>4,300</td>
</tr>
<tr>
<td>Newly diagnosed</td>
<td>1,100</td>
<td>1,100</td>
<td>1,100</td>
<td>1,100</td>
<td>1,100</td>
</tr>
<tr>
<td>Treatment-eligible fibrosis stages</td>
<td>≥ F2</td>
<td>≥ F0</td>
<td>≥ F0</td>
<td>≥ F0</td>
<td>≥ F0</td>
</tr>
<tr>
<td>New infections</td>
<td>700</td>
<td>700</td>
<td>700</td>
<td>700</td>
<td>700</td>
</tr>
<tr>
<td>Treatment-eligible ages</td>
<td>15+</td>
<td>15+</td>
<td>15+</td>
<td>15+</td>
<td>15+</td>
</tr>
<tr>
<td>SVR</td>
<td>95%</td>
<td>95%</td>
<td>95%</td>
<td>95%</td>
<td>95%</td>
</tr>
</tbody>
</table>
Calculations for the economic model are provided in Appendix Section 3 and briefly described here. To assess cost-effectiveness, QALYs were calculated. QALYs were based on time spent in various health states, using a health state utility value between 0 and 1 (8–12). The incremental cost-effectiveness ratio (ICER) was calculated as the net cost (the difference in direct costs between the scenario and the base case) divided by the net benefit (the difference in QALYs between the scenario and the base case). Achieving a net cost of zero was defined as the break-even point.

Disease burden outcomes were evaluated through to 2030, in line with the Global Health Sector Strategy targets for the elimination of HCV [8]. However, the economic impact was considered through to 2031 to ensure all costs associated with implementing the intervention scenario were fully realized. Medical costs were denominated in 2016 Swiss francs, using the exchange rate on December 31, 2016.

**Input parameters**

Input parameters were obtained from peer-reviewed literature or extracted from Swiss-specific sources. The HCV disease progression model inputs for Switzerland have been published previously [3]. In many instances, however, more recent data (number treated, number diagnosed, etc.) were available. All updated and novel parameters are described below and in table 2.

A full list of the input parameters required for the HCV disease progression model is provided in Appendix Section 1. In summary, there were approximately 39,500 chronic (HCV RNA-positive) cases in Switzerland in 2016 [1]. The percentage diagnosed in 2016 was estimated from Swiss FOPH notification data were considered as follows. In 2013, there were an estimated 30,200 diagnosed viraemic infections in Switzerland (after accounting for mortality) [17]. In 2013–2015, there were an average of 1,600 new HCV notifications to the Swiss FOPH [10]. Assuming a viraemic rate of 79.7% [9], this suggests an average of 1,300 new viraemic diagnoses annually. Removing cured HCV patients over the 2004–2015 period results in a range of 25,400–29,100 total diagnosed viraemic cases alive in 2015 (table 2). In 2016, there were an additional 1,400 newly notified cases, corresponding to approximately 1,116 newly diagnosed viraemic cases [10]. Thus, out of the estimated 39,500 persons living with HCV in 2016, about 67–77% had been diagnosed.

The number of patients treated annually was derived from pharmaceutical sales data, and reimbursement restrictions on the basis of fibrosis stage were confirmed through discussions with the FOPH and providers in Switzerland. In 2015, an estimated 2,300 (2,000–2,500) patients were treated in total. Approximately 1,280 of these were ≥F3 and the remainder were F2 [11]. In 2016, the number of treated patients dropped to 2,100 ≥F2 (table 2). As of Oc-

<table>
<thead>
<tr>
<th>Category</th>
<th>Item</th>
<th>Source</th>
<th>Year</th>
<th>Base Case</th>
<th>Sensitivity (run only where ranges are present)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease burden model parameters</td>
<td>Anti-HCV prevalence</td>
<td>[1]</td>
<td>2016</td>
<td>0.7</td>
<td>0.3–1.6% Beta-PERT</td>
</tr>
<tr>
<td></td>
<td>Viraemic rate</td>
<td>[9]</td>
<td></td>
<td></td>
<td>79.7% -</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2013–2015</td>
<td>Refer to original source for annual data</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2016</td>
<td>1,116</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2015</td>
<td>1,280 ≥F3</td>
<td>2,500 ≥F2 -</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2016</td>
<td>2,100 ≥F2</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Liver transplants</td>
<td>Swiss Transplant</td>
<td>2003–2016</td>
<td>Refer to original source for annual data</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liver transplants due to HCV</td>
<td>Personal communication</td>
<td></td>
<td>21.2%</td>
<td>18.2–49.2% Beta-PERT</td>
</tr>
<tr>
<td>Disease burden model validation</td>
<td>Incident liver cancer cases</td>
<td>National Institute for Cancer Epidemiology and Registration</td>
<td>1988–2012</td>
<td>Refer to original source for annual data</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HCC etiology</td>
<td>Geneva Tumour Registry</td>
<td>1990–2013</td>
<td>Refer to original source for annual data</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HCC due to HCV</td>
<td>[12]</td>
<td>1998–2012</td>
<td>44.5%</td>
<td>43.3–53.3% Beta-PERT</td>
</tr>
<tr>
<td>Economic modelling parameters</td>
<td>Multiplier for private costs</td>
<td></td>
<td></td>
<td>1.5</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>QALY health state utilities</td>
<td>See study</td>
<td></td>
<td></td>
<td>Beta-PERT</td>
</tr>
<tr>
<td></td>
<td>GDP per capita</td>
<td></td>
<td>2015</td>
<td>78,000</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Discounting</td>
<td></td>
<td></td>
<td>3%</td>
<td>0%, 3% Binomial</td>
</tr>
<tr>
<td></td>
<td>Staging / liver biopsy / fibroscan</td>
<td>[14, 16]</td>
<td>2016</td>
<td>256</td>
<td>218–294 Beta-PERT</td>
</tr>
<tr>
<td>Health state costs (CHF) (public)</td>
<td>Treatment cost (CHF)</td>
<td>[8]</td>
<td>2015</td>
<td>59,100</td>
<td>49,100–66,400 Beta-PERT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2016</td>
<td>51,400</td>
<td>42,700–61,300 Beta-PERT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2017</td>
<td>31,000</td>
<td>26,350–35,650 Beta-PERT</td>
</tr>
</tbody>
</table>
tober 2017, fibrosis restrictions were lifted, making all patients, regardless of their fibrosis stage, eligible for treatment. In 2017, it was estimated that 3,000 patients were treated (based on extrapolations of data provided by the Swiss Pharmacist Cooperative (OFAC), Swiss National Pharmacy Service (Mediservice) and IMS Health), an increase of 43% compared to 2016 as previously ineligible F0 and F1 patients received treatment.

All input parameters for the economic modelling are listed in table 2. QALY utilities were obtained from a 2016 cost-effectiveness model of US patients and were applied to this model by disease stage [13]. Data on the cost of healthcare for HCV patients by disease stage [3, 14] and diagnostic cost data, including all treatment-related tests such as polymerase chain reaction (PCR) testing, genotyping and fibrosis staging [15], were obtained from previous publications. As treatment regimens and outcomes improve, the number and types of treatment-related tests needed are expected to change. The timeline for these changes was divided into three waves, present (prior to 2018), near future (2018–2021) and pan-genotypic (after 2021).

The FOPH specialties list provided treatment costs by therapy type in 2016, when treatment was limited to ≥F2 patients, while October 2017 updates to the specialties list (corresponding to the change in reimbursement restrictions) were used to inform treatment costs for scenarios where ≥F0 patients were treated [6]. Discussions with the FOPH suggest that treatment costs decreased by 15% when treatment was expanded to F2 patients, so the treatment price of 59,100 CHF in 2015 (when treatment was restricted to ≥F3 patients) was assumed to be 15% higher than the baseline price in 2016 (51,400 CHF).

Characterizing uncertainty
Sensitivity analyses were carried out using Crystal Ball, an Excel add-in by Oracle. Beta-PERT distributions were used to model uncertainty in all study parameters, unless noted otherwise in table 2. A one-way sensitivity analysis was conducted to identify the variables that most heavily influenced the ICER. Additionally, a Monte Carlo simulation with 1,000 trials was used to determine the 95% uncertainty intervals (UIs).

Results
Disease burden analysis
The historical base case, with approximately 39,500 cases in 2016 and no change to the 2016 treatment paradigm, shows a decrease in the economic and disease burdens of HCV by 2031. The number of infected individuals declines by 35% while rates of DC, HCC and liver-related deaths (LRD) decrease 50–55% by 2031 (Appendix Section 2). In comparison, in the intervention scenario (Scenario 1), an 85% decline in the projected number of viraemic cases is expected between 2016 and 2031, with approximately 560, 710 and 1,000 incident cases of DC, HCC and LRD respectively averted over this period (Appendix Section 2).

Cost analysis
Under the historical base case, annual direct costs are projected to decrease from 150 million (95% UI: 132–170 million) CHF in 2016 to 90 million (95% UI: 65–111 million) CHF in 2031 (figure 1a). Cumulative direct costs, however, are projected to reach 1.7 billion (95% UI: 1.2–2.0 billion) CHF by 2031 (figure 1b, table 3). In Scenario 1, annual direct costs first increased to 175 million CHF in 2018, before declining to 44 million CHF by 2031 (figure 1a). Cumulative direct costs in this scenario are projected to reach 1.8 billion CHF by 2031 (figure 1b, Table 3). Considering direct costs only, Scenario 1 does not achieve break-even by 2031 (figure 1b).

Considering only direct costs, a treatment price of 27,900 CHF per patient was found to break even (yield zero net cost relative to the historical base case) in 2031 (figure 1b). The 27,900 CHF price was thus used to define Scenario 2. The impact of this was a reduction in annual direct costs compared with Scenario 1, with 163 million CHF incurred in 2018, dropping to 40 million CHF by 2031 (figure 1a). Cumulative direct costs reach 1.7 billion CHF by 2031, to match the historical base case (figure 1b, Table 3).

Treatment and laboratory costs in the historical base case were projected to decrease from 105 million (95% UI: 105 million–106 million) CHF annually to 61 million (95% UI: 53–69 million) CHF in 2031, a 43% decrease (figure 1c). In Scenario 1, the treatment and laboratory costs would increase from 110 million to 141 million CHF in 2018 before falling to 37 million CHF annually in 2031, a 65% decrease compared to 2016 (figure 1d). In Scenario 2, due to the lower treatment costs, the annual treatment and laboratory costs would peak at 128 million CHF from 2018 to 2021 before falling to 33 million CHF by 2031, a 70% decrease compared to 2016 (figure 1e).

In this model, more than 60% of viraemic cases were estimated to have been diagnosed as of 2016, with 1,120 new viraemic cases diagnosed annually. Assuming no change to screening strategies, annual costs will rise to just over 5 million CHF annually by 2021 (figures 1c, 1d and 1e). After 2021, these costs decline rapidly, and by 2023 annual costs are less than 125,000 CHF for all three scenarios. Because Scenarios 1 and 2 treat the same number of patients, they gain the same number of QALYs, with 163 million CHF incurred cumulatively by 2031 (figure 1f, table 3). The cost per QALY gained for both Scenarios 1 and 2 decrease over time as patients are cured. Additionally, the lifting of fibrosis restrictions means that fewer cases are progressing to the costlier advanced stages of disease. Under both scenarios, the cost per QALY gained drops below the cost-effectiveness threshold of 78,000 CHF in 2018 (figure 1g). Over the 15-year span, the cost per QALY gained was determined to be 2,200 CHF for Scenario 1 (and zero for Scenario 2) (table 3). This 15-year ICER of Scenario 1 indicates that it is highly cost-effective compared to the historical base case given a cost-effectiveness acceptability threshold of one GDP per capita of Switzerland, as seen in figure 1g. Scenario 2 was, by design, cost-saving (and highly cost-effective) relative to the base case.

Sensitivity analysis
In a sensitivity analysis, ten variables accounted for more than 99% of the uncertainty in the cost per QALY gained (15-year ICER) (figure 2) under Scenario 1. The rate of spontaneous clearance, rate of mild to moderate fibrosis progression, 2017 treatment price, HCV prevalence in 2016, healthcare costs for compensated cirrhosis and the
standardized mortality ratio (SMR) for blood transfusion recipients accounted for more than 90% of the uncertainty. All the variables considered in the analysis are listed in table 2, and the impact on the 15-year ICER is presented in figure 2.

**Discussion**

The complex and costly-to-manage end-stage outcomes of chronic HCV infection, combined with high DAA costs, have previously led some health systems to require evi-
dence of advanced liver fibrosis before authorizing new therapies [18–21]. This analysis sought to compare the impact of an intervention strategy of treating more patients in earlier fibrosis stages to the more restrictive base case. This was done by assessing the disease burden impact of this strategy, as well as the impact on direct costs and health effects (i.e. costs of reduced quality of life) over the next 15 years. Furthermore, the analysis sought to determine a drug price necessary for break-even by 2031.

Significant decreases in disease burden are estimated by 2031 for both the base case and the intervention scenario, with the intervention scenario seeing a larger impact, as expected. The decrease in late-stage liver disease in the base case scenario, however, is in contrast to previous analyses which reported a reduction in viraemic cases, but 50–85% increases in cases of DC, HCC and LRD by 2030 [3]. The current decrease in disease burden is likely due to increasing efforts in Switzerland to expand access to HCV diagnosis and treatment. Estimates from the FOPH suggest that 1,300 new viraemic cases were diagnosed annually between 2012 and 2015, and up to 2,000 ≥F2 patients were treated with DAAs in 2016, compared to 1,050 newly diagnosed and 1,100 treated patients, projected for the same years from prior studies [3, 10, 11, 17].

Direct costs were largely driven by treatment expansion. In the base case, annual direct costs decline over the 2017–2020 period due to the decreasing number of individuals already diagnosed and available to be treated. After 2020, the base case assumes no expansion of screening or diagnostic efforts and no increase to the number of patients treated, resulting in an equilibrium of direct costs (figure 1). By comparison, treatment and laboratory staging costs in the intervention scenarios remain greater than 130 million CHF annually until 2025, at which point they drop drastically as the limits of diagnosis and treatment are reached in Switzerland. The impact of the expanded access to treatment and cure in the intervention scenarios is also seen in the steady decline in healthcare costs, as cases of DC and HCC, as well as of liver transplantations, are prevented. By 2031, healthcare costs in the base case are four times lower than in the intervention scenario.
times higher than in either intervention scenario. The intervention’s higher upfront costs are therefore offset by reductions in future healthcare costs. In all three scenarios, a major change in screening costs occurs between 2021 and 2023, falling from more than 5 million CHF annually to less than 125,000 CHF annually. These costs are estimated by assuming that the current number of patients diagnosed annually is maintained, and uses formulas to estimate the number of screenings needed from the proportion of prevalent and diagnosed cases [15].

Expanding treatment access to all patients aged 15 years and over, regardless of fibrosis stage, over the next 15 years, was found to be cost-effective by 2018 at the 31,000 CHF price. While this is not sufficient to break even by 2031, it lends further credence to other analyses which have shown that early treatment of HCV is not only beneficial to disease burden, but also cost-effective [13, 22, 23]. Net-zero cost analysis found that a 27,900 CHF treatment price could achieve break-even in direct costs by 2031. Finally, this analysis has some limitations which should be considered when evaluating the results. The high diagnosis coverage (66%) does not necessarily translate to patients linked to care, meaning that some work may still be required to identify patients for treatment. In addition, the analysis assumed no risk of reinfection after cure, an assumption which could lead to an overestimation of cost-effectiveness. Another limitation of this analysis is that the results do not consider extrahepatic manifestations of HCV, associated lost productivity, or other aspects of societal return on investment. Recent studies suggest that extrahepatic manifestations contribute substantially to the economic burden of HCV [24, 25]. Achieving SVR, especially at an early stage of disease, can attenuate the associated disease and economic burdens of these extrahepatic manifestations [26, 27]. Including this in the analysis would likely show even greater cost savings. Similarly, if we had included the loss in productivity and decreased societal engagement (due to stigma, strained relationships, etc.) associated with ongoing HCV infection (and subsequently improved by achieving SVR), the cost savings associated with treating HCV would be expected to improve. Lastly, the analysis does not incorporate any future changes in price associated with the introduction of generic drugs. Beginning in 2026, treatment prices are estimated to drop to 70% of the initial 2016 prices due to patent expiration and the use of generics. This would make the key outcomes of the economic impact analysis more favourable. However, it is possible that new therapies will be introduced before the patent expiration, which would counterbalance the effect of generic price reductions.

Conclusions

This analysis shows baseline HCV disease burden in Switzerland declining over the next 15 years, even with treatment restricted to ≥F2 patients. Expanding treatment to ≥F0 patients and increasing the number of treated patients (considering a price of 27,900–31,000 CHF per treatment) will result in a larger impact on disease burden and is cost-effective or cost-saving when considering a variety of measures. This confirms that further reductions in treatment prices improve cost-effectiveness and create conditions suitable for positive returns on the investment. To supplement this cost-effectiveness analysis, a comprehensive budget impact analysis would be essential to determine the financial consequences and affordability of implementing such strategies.

Acknowledgements

We are grateful to Dr. Jörg Indermitte from the Federal Office of Public Health and Ivane Gankrielidze from the Center for Disease Analysis Foundation (CDAF) for their contributions to the development of this analysis. Additionally, we would like to thank Helen Nde and Sarah Robbins from CDAF for their help drafting and reviewing the manuscript. Finally, we appreciate the input of Prof. Beat Müllerhaup, Dr. Florian Blih, Prof. Daniel Lavanchy and Dr. David Semela, who provided data and input for the disease burden analysis.

Funding source

This work was funded by the Swiss Federal Office of Public Health

Conflicts of interest

S. Blach and H. Razavi are employees of the Center for Disease Analysis Foundation (CDAF) and have not received any remuneration from pharmaceutical companies. H. Razavi has been a member of advisory boards for Gilead, AbbVie and Janssen pharmaceuticals; all proceeds went to the CDAF. He is the managing director of Center for Disease Analysis (CDA). The CDAF has received grants from CDC Foundation, John C Martin Foundation, The Association of State and Territorial Health Officials (ASTHO), Zeschan Foundation, Vaccine Impact Modelling Consortium, WHO, WHO Geneva, Swiss Federal Office of Public Health, Brazil MoH, Center for Disease Analysis and private donors. The CDA has received research funding from Gilead Sciences, AbbVie and Interceptor Pharma. P. Brüggmann is a consultant/advisor and has received research/travel grants from AbbVie, Gilead Sciences and Merck/MSD. F. Negro has received research funding from Gilead Sciences and is a consultant/advisor for Gilead, AbbVie and MSD.

References


